media – Page 188 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan

Swedish biotech Vicore Pharma has entered an exclusive licensing agreement for the Japanese rights for its idiopathic pulmonary fibrosis (IPF) therapy C21 with Nippon Shinyaku. Vicore will receive a $10m upfront payment and will be in line to receive up to $275m in development and commercial milestone-based payments. The company will also be placed to get tiered royalties that extend into “the low 20s” based on annual net sales of C21 in Japan, as per a 9 February press release. As per the agreement, Nippon will hold exclusive rights to develop and commercialise C21 in Japan. The company will be responsible for operational and financial costs for developing C21 in the country. Nippon will also contribute financially to the Japanese trial sites and patients in the global late-stage development of C21. Following the news, Vicore’s stock was up over 18% in trading today. The company’s market ...
- Source: https://www.pharmaceutical-technology.com/news/vicore-licenses-idiopathic-pulmonary-fibrosis-therapy-to-nippon-in-japan/?cf-view
- 137
- February 12, 2024
AstraZeneca posts 81% rise in FY 2023 profit after tax

AstraZeneca has reported a significant 81% rise in profit after tax, reaching $5.96bn for the fiscal year (FY) 2023 from $3.29bn in the previous year. Despite a $3.73m decline in the sales of Covid-19 medicines, the company’s total revenue for the full year 2023 grew by 6% to $45.81bn, up from $44.35bn in FY 2022. Excluding Covid-19 medicines, AstraZeneca saw a 15% increase in total revenue. The company experienced growth across oncology, where revenues rose by 21%, cardiovascular, renal and metabolism (a rise of 18%), respiratory and immunology (a rise of 10%) and rare disease (a rise of 12%). Reported earnings per share (EPS) stood at $3.84, an 81% increase from the $2.12 reported in the previous year. Core EPS, a key profitability measure, rose 15% to $7.26. The company’s earnings before interest, taxes, depreciation and amortisation also saw a notable increase of 47% ...
- Source: https://www.pharmaceutical-technology.com/news/astrazeneca-fy-2023-profit-after-tax/?cf-view
- 175
- February 12, 2024
Blood biomarkers in TGF-β pathway identify hidden liver cancer risk

A new research paper was published in Genes & Cancer on February 5, 2023, entitled, “Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.” Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer worldwide but is often diagnosed at an advanced incurable stage. Yet, despite the urgent need for blood-based biomarkers for early detection, few studies capture ongoing biology to identify risk-stratifying biomarkers. In this new study, researchers Xiyan Xiang, Krishanu Bhowmick, Kirti Shetty, Kazufumi Ohshiro, Xiaochun Yang, Linda L. Wong, Herbert Yu, Patricia S. Latham, Sanjaya K. Satapathy, Christina Brennan, Richard J. Dima, Nyasha Chambwe, Gulru Sharifova, Fellanza Cacaj, Sahara John, James M. Crawford, Hai Huang, Srinivasan Dasarathy, Adrian R. Krainer, Aiwu R. He, Richard L. Amdur, and Lopa Mishra, from The Feinstein Institutes for Medical Research, Cold Spring Harbor Laboratory, University of Maryland, University ...
- Source: https://www.news-medical.net/news/20240209/Blood-biomarkers-in-TGF-ceb2-pathway-identify-hidden-liver-cancer-risk.aspx
- 173
- February 12, 2024
A budget friendly bioprocess control station for microbial applications

Distek, Inc., a leader in laboratory pharmaceutical instruments for over 48 years, proudly presents the BIOne 250 Bioprocess Controller, designed for microbial applications. This latest model is a process optimized design of our well-established BIOne 1250 benchtop bioreactor system, offering an approachable solution to meet the nuanced requirements of advanced microbial bioprocessing. This new addition to the Distek bioprocessing instrument family is designed as a cost-effective solution for microbial bioprocess applications. Building on the success of the award-winning design of the BIOne 1250 controller, the BIOne 250 provides sophisticated functionality to laboratories and research facilities of all sizes. The controller retains the popular user interface of the BIOne 1250 via a remote PC or monitor. This unique capability supports the management of multiple bioreactors from a single central screen. A standout feature of the BIOne 250 is its scalability, accommodating the evolving needs of bioprocess applications, making it suitable for ...
- Source: https://www.news-medical.net/news/20240210/Discover-the-BIOne-250-A-budget-friendly-bioprocess-control-station-for-microbial-applications.aspx
- 89
- February 12, 2024
Study reveals AI can predict patients’ survival in glioblastoma

The aggressive brain cancer is responsible for over 3,000 cases in the UK every year Researchers from King’s College London (KCL) have developed an artificial intelligence (AI)-based model that can predict adult brain cancer patients’ rates of survival after receiving radiotherapy treatment. Published in Neuro-Oncology, researchers applied deep learning to predict whether glioblastoma patients would survive eight months. Responsible for around 3,200 cases every year in the UK, glioblastoma is a very aggressive and difficult-to-treat cancer, with just one in four patients surviving over one year after diagnosis. Currently, patients are regularly and routinely tested to see whether chemotherapy is effective or not. However, some patients can suffer from harmful side effects as a result of chemotherapy. Instead, by giving patients an instantaneous and accurate prediction from a single routine MRI scan, the AI will allow doctors to identify patients who would not benefit from chemotherapy and try a different ...
- Source: https://pharmat.com/news/study-reveals-ai-can-predict-patients-survival-in-glioblastoma/
- 101
- February 12, 2024
Study reveals SARS-CoV-2 can infect dopamine neurons causing senescence

Dopamine neuron senescence is a hallmark of Parkinson’s disease Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Columbia University Vagelos College of Physicians and Surgeons have reported that SARS-CoV-2 can infect dopamine neurones in the brain, triggering senescence. Long COVID patients should be monitored for an increased risk of developing Parkinson’s disease (PD)-related symptoms, as dopamine neuron senescence is a hallmark of the condition. The study revealed that dopamine neurons that are infected with SARS-CoV-2, the virus that causes COVID-19, stop working and send out chemical signals that cause inflammation, triggering senescence, when a cell loses the ability to grow and divide. Neurons produce dopamine, a neurotransmitter that acts on areas of the brain and causes feelings of pleasure, motivation, memory, sleep and movement. Damage to these neurons is also associated with PD, a neurodegenerative disorder that progressively damages parts of the brain. After generating multiple cell types from ...
- Source: https://news.weill.cornell.edu/news/2024/01/sars-cov-2-can-infect-dopamine-neurons-causing-senescence
- 169
- February 12, 2024
New programme shown to help dementia patients live independently

The neurodegenerative condition currently affects over 944,000 people in the UK A new programme led by Queen Mary University of London and funded by the Alzheimer’s Society has received positive trial results that could benefit carers and patients living with dementia. The New Interventions for Independence in Dementia (NIDUS-Family) programme was successful in supporting patients and carers to achieve their goals compared to those who received usual care. Affecting more than 944,000 people in the UK, dementia is a neurodegenerative disease that impairs a person’s ability to remember, think or make decisions on a daily basis. Set up at University College London and now running at Queen Mary’s University London, NIDUS-Family aims to understand how to support carers who look after those with dementia at home. Researchers tested the programme on a small number of participant pairs with over 300 people living with dementia and their unpaid carers. The first ...
- Source: https://pharmatimes.com/news/new-programme-shown-to-help-dementia-patients-live-independently/
- 91
- February 11, 2024
Regeneron’s linvoseltamab application accepted for review

Regeneron Pharmaceuticals marketing authorisation application (MAA) for linvoseltamab has received acceptance for review from the European Medicines Agency (EMA) to treat adults with r/r MM. Linvoseltamab is a bispecific antibody designed to target and destroy cancer cells by bridging the B cell maturation antigen on MM cells with CD3 (cluster of differentiation 3, a protein complex)-expressing T cells. The MAA submission is based on findings from the Phase I/II LINKER-MM1 clinical trial of linvoseltamab in r/r MM patients. The open-label, multicentre, dose-escalation and dose-expansion study is designed to evaluate the investigational drug in patients who have undergone multiple prior treatments. All 282 enrolled trial subjects had received a minimum of three lines of therapy or were considered triple refractory. They subsequently received linvoseltamab through an initial step-up dosing regimen, followed by a full dose. The completed Phase I portion of the trial evaluated the tolerability, safety ...
- Source: https://www.echnology.com/news/regeneron-linvoseltamab-application-review/
- 96
- February 11, 2024
Hemogenyx gets reprieve as FDA lifts clinical hold on AML CAR-T therapy

Hemogenyx has received the all-clear from the US Food and Drug Administration (FDA) to begin a Phase I clinical trial of its acute myeloid leukaemia (AML) chimeric antigen receptor (CAR) T-therapy in the US. In June 2023, the US FDA placed a clinical hold on the trial for HEMO-CAR-T, requesting additional information from Hemogenyx after a splicing deficiency during manufacture of the lentivirus used to produce CAR-T cells. Hemogenyx produced a plan, supported by laboratory tests to address FDA’s concerns in August 2023, which was accepted the following month. In January, the London, UK-based biopharma issued a complete response to the agency to lift the hold. Hemogenyx’s stock price has increased by 62% following the announcement of the lifting of the hold today (9 February) since the market close yesterday.CAR-T therapies have been hitting the headlines recently after the FDA launched an investigation into the incidence of potentially associated secondary ...
- Source: drugdu
- 140
- February 10, 2024
Multiplexed PCR Test for Pathogen Detection and Antibiotic Resistance Helps Deliver Rapid UTI Treatment

Individuals suffering from urinary tract infections (UTIs) face the risk of continued pain and discomfort, chronic infections, kidney infections, and in severe cases, sepsis. This makes timely and accurate diagnosis of UTIs crucial. Now, a novel multiplexed PCR test capable of detecting 26 pathogens and 12 antibiotic resistance gene markers can assist clinicians in administering rapid UTI treatment. PathogenDx (Scottsdale, AZ, US) has launched D3 Array-UTI which is based on the company’s patented Dynamic Dimensional Detection (D3 Array) technology. This cutting-edge multiplexed molecular diagnostics technology offers triple-redundant testing for quality assurance and provides both qualitative as well as quantitative results in a single reaction. Additionally, it offers automated, cloud-based data analysis, reporting, and management. PathogenDx’s advanced microarray testing platform is designed for human diagnostics (for research use only), as well as for the food and agricultural industries. It can rapidly detect and identify up to 50 pathogens simultaneously in a ...
- Source: drugdu
- 69
- February 10, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.